Novel implications of Lingo-1 and its signaling partners in schizophrenia

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Fernandez Enright, F ^a,b   Andrews, J L ^a,b   Newell, K A ^a,b   Pantelis, C ^c   Huang, X F ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Lingo 1; Myt1; Nogo receptor; p75 TROY; Schizophrenia; WNK1

Indexed keywords

BIOLOGICAL MARKER; LINGO 1 PROTEIN; MYELIN BASIC PROTEIN; MYELIN TRANSCRIPTION FACTOR 1; NOGO RECEPTOR; PLASMA PROTEIN; PROTEIN KINASE WNK1; PROTEIN P75; TUMOR NECROSIS FACTOR RECEPTOR ORPHAN Y; UNCLASSIFIED DRUG; LINGO1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN DOMAIN CONTAINING PROTEIN 1; RECEPTOR; REGULATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MIDDLE AGED; PATHOGENESIS; PREFRONTAL CORTEX; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TISSUE PREPARATION; AGED; HEALTH CARE FACILITY; METABOLISM; PATHOLOGY; PHYSIOLOGY; BRAIN REGION; DORSOLATERAL PREFRONTAL CORTEX; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; PATHOPHYSIOLOGY;

ADULT; AGED; HIPPOCAMPUS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TISSUE BANKS;

EID: 84892991060     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.121     Document Type: Article

References (50)

1. Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 2005; 31: 672-696. (Pubitemid 41253318)
2. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751. (Pubitemid 32295047)
3. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805. (Pubitemid 37093922)
4. Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte- and astrocyteassociated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr Res 2009; 112: 54-64.
5. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55: 597-610. (Pubitemid 32888378)
6. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G et al. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 2004; 56: 41-45. (Pubitemid 38813404)
7. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52. (Pubitemid 32451739)
8. Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 2003; 53: 412-421. (Pubitemid 36263015)
9. Walterfang M, Wood SJ, Velakoulis D, Neuropathological Pantelis C. neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci Biobehav Rev 2006; 30: 918-948. (Pubitemid 44292852)
10. Walterfang M, Velakoulis D, Whitford TJ, Pantelis C. Understanding aberrant white matter development in schizophrenia: an avenue for therapy? Exp Rev Neurother 2011; 11: 971-987.
11. Takahashi N, Nielsen KS, Aleksic B, Petersen S, Ikeda M, Kushima I et al. Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase ? to schizophrenia. Biol Psychiatry 2011; 70: 626-635.
12. Pearlson GD, Petty RG, Ross CA, Tien AY. Schizophrenia: a disease of heteromodal association cortex? Neuropsychopharmacology 1996; 14: 1-17. (Pubitemid 26047181)
13. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745-751. (Pubitemid 43085840)
14. Rudick RA, Mi S, Sandrock AW Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Exp Opin Biol Ther 2008; 8: 1561-1570.
15. Yamashita T, Higuchi H, Tohyama M. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J Cell Biol 2002; 157: 565-570. (Pubitemid 34839785)
16. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002; 420: 74-78. (Pubitemid 35291442)
17. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N et al. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 2005; 45: 353-359. (Pubitemid 40188203)
18. Hu F, Strittmatter SM. Regulating axon growth within the postnatal central nervous system. Semin Perinatol 2004; 28: 371-378. (Pubitemid 40037563)
19. Barrette B, Vallières N, Dubé M, Lacroix S. Expression profile of receptors for myelin-associated inhibitors of axonal regeneration in the intact and injured mouse central nervous system. Mol Cell Neurosci 2007; 34: 519-538. (Pubitemid 46483077)
20. Zhang Z, Xu X, Zhang Y, Zhou J, Yu Z, He C. LINGO-1 interacts with WNK1 to regulate nogo-induced inhibition of neurite extension. J Biol Chem 2009; 284: 15717-15728.
21. Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry 2009; 14: 1083-1094.
22. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, Sabatti C, Geurts van Kessel A et al. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet 2008; 83: 504-510.
23. Sinibaldi L, De Luca A, Bellacchio E, Conti E, Pasini A, Paloscia C et al. Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat 2004; 24: 534-535.
24. Budel S, Padukkavidana T, Liu BP, Feng Z, Hu F, Johnson S et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci 2008; 28: 13161-13172.
25. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelinassociated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 2006; 21: 531-540. (Pubitemid 43277536)
26. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004; 7: 221-228. (Pubitemid 38280445)
27. Chambers JS, Perrone-Bizzozero NI. Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem Res 2004; 29: 2293-2302. (Pubitemid 40036903)
28. Uranova NA, Vikhreva OV, Rachmanova VI, Orlovskaya DD. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study. Schizophr Res Treatment 2011; 2011: 325789.
29. Velakoulis D, Wood SJ, Wong MTH, McGorry PD, Yung A, Phillips L et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139-149. (Pubitemid 43213875)
30. Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T et al. Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 2010; 44: 59-70.
31. Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 2010; 167: 1479-1488.
32. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S et al. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 2007; 66: 35-46. (Pubitemid 46066787)
33. Zalesky A, Fornito A, Seal ML, Cocchi L, Westin CF, Bullmore ET et al. Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry 2011; 69: 80-89.
34. Makinodan M, Yamauchi T, Tatsumi K, Okuda H, Takeda T, Kiuchi K et al. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 978-985.
35. Kato T, Abe Y, Sotoyama H, Kakita A, Kominami R, Hirokawa S et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry 2011; 16: 307-320.
36. Loov C, Fernqvist M, Walmsley A, Marklund N, Erlandsson A. Neutralization of LINGO-1 during In Vitro Differentiation of Neural Stem Cells Results in Proliferation of Immature Neurons. PLoS ONE 2012; 7: e29771.
37. Ji B, Li M, Wu WT, Yick LW, Lee X, Shao Z et al. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci 2006; 33: 311-320. (Pubitemid 44692494)
38. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004; 23: 3270-3281. (Pubitemid 39209151)
39. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and liganddependent EGFR activity. Oncogene 2007; 26: 368-381. (Pubitemid 46122827)
40. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 2002; 7: 673-682. (Pubitemid 34984943)
41. Parlapani E, Schmitt A, Erdmann A, Bernstein H-G, Breunig B, Gruber O et al. Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Res 2009; 1301: 126-134.
42. Thomas EA. Molecular profiling of antipsychotic drug function. Mol Neurobiol 2006; 34: 109-128.
43. Trifunovski A, Josephson A, Ringman A, Brene S, Spenger C, Olson L. Neuronal activity-induced regulation of Lingo-1. Neuroreport 2004; 15: 2397-2400. (Pubitemid 39488927)
44. Zhu H-Y, Guo H-F, Hou H-L, Liu Y-J, Sheng S-L, Zhou J-N. Increased expression of the Nogo receptor in the hippocampus and its relation to the neuropathology in Alzheimer's disease. Hum Pathol 2007; 38: 426-434. (Pubitemid 46227533)
45. Lu B, Martinowich K. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp 2008; 289: 119-195.
46. Dunham JS, Deakin JFW, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009; 43: 1175-1184.
47. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H et al. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 2003; 100: 14109-14114. (Pubitemid 37499199)
48. Benes FM. Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull 1989; 15: 585-593. (Pubitemid 20066726)
49. Hunsberger J, Austin DR, Henter ID, Chen G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 2009; 11: 333-348.
50. Emamian ES . AKT/GSK3 signaling pathway and schizophreni a. Front Mol Neurosci 2012; 5: 33.